Customization of MIT Mouse Recombinant mAb


Preparing humanized antibodies on the basis of mouse-derived antibodies is one of the mainstream antibody drug technologies. We provide Magnetic & Immunization & Tandem (MIT) mouse monoclonal antibody customization service to address problems appeared from conventional mouse-derived antibody (hybridoma monoclonal antibody) preparation technologies, such as long preparation period, heavy screening workload, and small amount of candidate antibodies.

Service Highlights

1. Clear Antibody Sequence Reducing Redundant Screening

  • Genetic engineering and phage display technology are used to obtain the gene sequence of the antibody directly, reducing unnecessary screening.

 

2. Three Months Faster than Hybridoma to Speed up Drug R&D

  • This service takes only 2 months for library construction and screening, which is nearly 3 months faster than the screening process of hybridoma technology and can speed up the R&D progress significantly.

 

3. Delivery of Dozens to Hundreds of High-Affinity Lead Antibody Molecules

  • Dozens to hundreds of candidate molecules can be obtained for each target using an arrayed multi-library approach and a multi-species library screening strategy. In this way, the candidate antibodies have higher affinity at pM level typically.

 

4. Immunization through Multiple Sites\Species to Increase Species Cross-activity of Candidate Antibodies

  • With up to 4 mouse strains, multiple immunization approaches, species of immunogens, and screening methods, it’s easier to increase species cross-activity of antibody molecules.

 

5. Ensure Drug Developability through Eukaryotic Expression System and Cellular Level Verification

  • The candidate molecules are expressed through eukaryotic system and followed by physicochemical characteristics and cellular function testing to ensure the delivered lead antibody has good drug developability.



Popular articles

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more
Shanghai Model Organisms Jinshan R&D Base officially put into operation

After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.

Learn more